3.1 Antibody-drug conjugates 3.1.1 Rova-T. Rova-T, the first DLL3-targeting ADC developed for extensive-stage SCLC (ES-SCLC), combines a humanized monoclonal antibody with a DNA cross-linker payload ...

Doctors may treat neuroendocrine tumours of the pancreas with a drug called everolimus. It is a type of biological therapy. It stops a protein called mTOR from working properly which can help to stop ...

Its role in the transdifferentiation of prostate and lung adenocarcinoma into neuroendocrine prostate cancer (NEPC) and small cell lung cancer (SCLC) remains unexplored. Here, we identified circRMST ...

The Australian share market closes just a few points lower after retreating from record highs. The Australian dollar rose above 65 US cents as the greenback fell against other major currencies.

BackgroundGastrointestinal neuroendocrine tumor (GI-net) is a rare heterogeneous tumor, and there is a lack of models to predict its prognosis. ... Pancreas. (2010) 39:707–12. doi: ...

Actor Vibhu Raghave, best known for 'Nisha Aur Uske Cousins', passed away on June 2 in Mumbai after his three-year-long battle with cancer. The actor was diagnosed with Stage 4 neuroendocrine ...

Television actor Vibhu Raghave, known for the Star Plus drama show Nisha Aur Uske Cousins (2014), died on June 2 after a long battle with stage 4 colon cancer. He was 37. Television actress Saumya ...

In this work, a nanoplatform (FeCORM NPs) loaded with an iron-carbonyl complex was constructed. By exploiting chemodynamic therapy (CDT) and immunogenic cell death (ICD)-induced immunotherapy (IMT), ...

At the cutoff date (November 20, 2024), the ORR was 31.4% (complete response [CR], 5.9%; partial response [PR], 25.5%). Overall, 79.3% of patients had tumor burden reduction; 16 had deepened responses ...

Just over six months after BioNTech bought out its development partner Biotheus to acquire solid tumor bispecific BNT327, Bristol Myers Squibb is dropping $1.5 billion upfront plus another $2 billion ...

Title: ZL-1310, a DLL3 ADC, in patients with extensive stage small cell lung cancer: Ph1 trial update Presenter: Manish R. Patel, M.D., Florida Cancer Specialists/Sarah Cannon Research Institute, ...

The novel trial design used ctDNA monitoring at the time of routine tumor scans to identify patients for early signs of endocrine resistance and the emergence of ESR1 mutations. Following detection of ...